Publications by authors named "Y Fujieda"
Muscle vasculitis in patients with polymyalgia rheumatica; three case series.
Mod Rheumatol Case Rep
December 2024
Article Synopsis
- - Polymyalgia rheumatica (PMR) is an inflammatory disorder marked by muscle pain and stiffness, mainly affecting the hip and shoulder areas, with high levels of CRP and ESR, but its exact causes are still unclear.
- - The report discusses three PMR patients who didn't respond well to standard treatments, presenting common symptoms such as muscle pain and weakness, and elevated CRP levels without increased creatine kinase.
- - Examination of muscle samples from these patients revealed signs of vasculitis, suggesting that muscular limited vasculitis (MLV) could be a potential underlying issue in these difficult-to-treat PMR cases.
Article Synopsis
- The study aimed to collect real-world data on VEXAS syndrome, focusing on disease activity, treatments, remission rates, and adverse events over a prospective period.
- Researchers enrolled suspected patients in Japan, utilizing a new disease activity measure (VEXASCAF) and recorded various health metrics, including UBA1 gene variant analysis.
- Out of 55 patients, 30 were found to have pathogenic UBA1 variants, with limited remission reported, frequent adverse events including deaths and infections, and a need for high-dose glucocorticoids to manage symptoms.
Article Synopsis
- This study focused on the protein levels of HTRA1 and TGF-β in the vitreous humor of patients suffering from various chorioretinal vascular diseases compared to control patients.
- It found that HTRA1 and VEGF levels were significantly higher in the disease group, while TGF-β2 levels showed no significant difference between groups.
- The research highlighted a strong correlation between HTRA1 and TGF-β2 levels, suggesting a potential relationship worth further investigation.
Objectives: Primary antiphospholipid syndrome (PAPS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity. Although PAPS is distinct from systemic lupus erythematosus (SLE), the two conditions share clinical features and susceptibility genes. Progression from PAPS to SLE is well-recognized.
View Article and Find Full Text PDFObjectives: Hydroxychloroquine (HCQ) is recommended at a target dose of 5 mg/kg per actual body weight to reduce the risk of retinopathy in systemic lupus erythematosus (SLE). However, the efficacy of HCQ has been established at doses of 6.5 mg/kg per ideal body weight.
View Article and Find Full Text PDF